Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Arman T. Askari"'
Autor:
Arman T. Askari, Adrian W. Messerli
The second edition of this key resource provides a broad and fundamental overview of basic cardiovascular (CV) hemodynamic principles with a focus on clinical assessment of CV physiology. Extensively updated, the book includes new coverage on noninva
Autor:
Arman T. Askari, Anna M. McDivit
Publikováno v:
Cleveland Clinic Journal of Medicine. 76:564-574
He has been taking good care of himself, but 1 year ago his ejection fraction was 60% and now it is 35%. He also has a new left bundle branch block. What is the cause?
Autor:
Matthew A. Kaminski, Amy Hsu, Michael J. Riley, Mehdi H. Shishehbor, Arman T. Askari, A. Michael Lincoff
Publikováno v:
American Heart Journal. 158:238-243
The long-term prognostic significance of early (48 hours) ventricular fibrillation (VF) or sustained ventricular tachycardia (VT) in patients with an acute myocardial infarction remains controversial. Emerging data suggest that some of the benefit of
Publikováno v:
Cleveland Clinic Journal of Medicine. 75:145-152
A previously healthy, relatively young man has had a stroke. What is the cause and what should be done?
Autor:
Arman T. Askari, Amar Krishnaswamy
Publikováno v:
Cleveland Clinic Journal of Medicine. 74:521-528
This case highlights the importance of thorough history-taking and the need to maintain a broad differential diagnosis, even if the test results seem definitive.
Publikováno v:
Journal of the American College of Cardiology. 49(3):279-289
Acute coronary syndromes represent a complex phenotype involving the interplay of many elements. The risk of developing an acute coronary syndrome and related complications has been defined by variables such as age, diabetes, smoking history, serum c
Autor:
P. Peter Borek, Deepak L. Bhatt, Arman T. Askari, Anthony A. Bavry, Girish R. Mood, Dharam J. Kumbhani
Publikováno v:
American Journal of Cardiovascular Drugs. 7:135-141
This study sought to determine if the initiation of statin (HMG-CoA reductase inhibitor) therapy during acute coronary syndromes reduces long-term mortality and other adverse cardiac outcomes. Initiation of statin therapy during acute coronary syndro
Publikováno v:
Journal of Thrombosis and Thrombolysis. 22:151-154
Glycoprotein (GP) IIb/IIIa inhibitors have been shown to reduce morbidity and mortality in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). With their widespread use, there is a growing body of literature d
Publikováno v:
Journal of the American College of Cardiology. 48(7):1319-1325
Benefit of Early Invasive Therapy in Acute Coronary Syndromes: A Meta-Analysis of Contemporary Randomized Clinical TrialsAnthony A. Bavry, Dharam J. Kumbhani, Andrew N. Rassi, Deepak L. Bhatt, Arma...
Autor:
Hitinder S. Gurm, Danielle M. Brennan, Neil S. Kleiman, A. Michael Lincoff, Eric J. Topol, Dean J. Kereiakes, Herbert D. Aronow, Arman T. Askari, James E. Tcheng
Publikováno v:
The American Journal of Cardiology. 94:30-34
Anemia and renal insufficiency impart an increased risk of mortality in patients with congestive heart failure. There is a paucity of data on the mortality hazard associated with anemia and renal insufficiency in patients undergoing percutaneous coro